DalCor Pharmaceuticals   Report issue

For profit Phase 3
Founded: Montreal Canada (2015)

Organization Overview

First Clinical Trial
2016
NCT02525939
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

DalCor Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

dalcetrapib (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1